R&D Locations: CovX, San Diego, CA

CovX is one of two biotechnology units within Pfizer Worldwide Research & Development, making a unique contribution to the pipeline by designing innovative bioconjugate products. It creates multifunctional biotherapeutics that are engineered to optimize efficacy, safety and compliance.

Collaborating with other Pfizer sites, CovX scientists combine skills in peptide innovation and optimization with state-of-the-art bioconjugation capabilities to provide therapies tailor made for therapeutic areas such as oncology and metabolic disease. Continuing innovation on the part of the staff has provided multiple new platforms that can be further exploited specifically for bifunctional/multifunctional capability.

Since being acquired by Pfizer in 2008, CovX has progressed several molecules into clinical phases of development including CVX-060, an antiangiogenesis agent for cancer into Phase Ib/II trials and CVX-096, a drug for the treatment of diabetes into Phase I.